Thymidine phosphorylase expression and effect of doxifluridine: a phase II study

Oncol Rep. 2001 Jul-Aug;8(4):753-8. doi: 10.3892/or.8.4.753.

Abstract

Doxifluridine (5'-DFUR), an active intermediate metabolite of capecitabine, is converted to 5-fluorouracil by thymidine phosphorylase (TP). We used immunohistochemical staining to investigate the relation between TP expression and 5'-DFUR effects in 40 patients with advanced/recurrent lung metastases from colorectal cancer. Cox regression analysis suggested that TP-positive cancer cells (risk ratio 3.72), were independent factors in survival whereas factors in progression-free survival were TP-positive cancer cells (2.93), and TP-positive stromal cells (0.24). It is suggested that TP expression in cancer cells and in stromal cells are opposite prognostic factors in patients treated with 5'-DFUR.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / enzymology
  • Colorectal Neoplasms / pathology
  • Disease-Free Survival
  • Female
  • Floxuridine / therapeutic use*
  • Humans
  • Immunoenzyme Techniques
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / secondary
  • Male
  • Middle Aged
  • Survival Rate
  • Thymidine Phosphorylase / metabolism*
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Floxuridine
  • Thymidine Phosphorylase
  • doxifluridine